Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track - Formal Notification Received of Sebetralstat EU Orphan Drug Status - KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals (KALV) Provides Operational Update and Fiscal Year Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track –– Formal Notification Received of Sebetralstat EU Orphan Drug Status –CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused.
- Patrick A. Treanor Appointed Effective Immediately - - Dan Soland Resigns in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused